Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QCDIP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2017089890A1 ADC90
|
|||||
| Synonyms |
Trastuzumab_compound 25f (DAR 4)
Click to Show/Hide
|
|||||
| Organization |
LegoChem Biosciences, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Gastric cancer [ICD11:2B72]
Investigative
Ovarian cancer [ICD11:2C73]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
WO2017089890A1_ADC90 linker
|
|||||
| Conjugate Type |
Site-specific conjugation through nucleophilic lysines.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.